{"entity":{"id":"socazolimab","kind":"drug","name":"Socazolimab","aka":[],"tldr":"Socazolimab is Lee's Pharmaceutical's PD-L1 antibody, in phase 3 trials in China for extensive-stage small cell lung cancer and recurrent cervical cancer.","summary":"Socazolimab (ZKAB001), licensed by Lee's Pharmaceutical from Sorrento, is a fully human PD-L1 antibody. Its phase 3 programme in China includes first-line extensive-stage small cell lung cancer with chemotherapy and recurrent or metastatic cervical cancer; earlier trials included osteosarcoma. OnCo records its Chinese regulatory status only where a source states it.","status":"phase-3","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Socazolimab","url":"https://clinicaltrials.gov/search?intr=ZKAB001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cervical","sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06459687"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"code":"ZKAB001","modality":"Anti-PD-L1 monoclonal antibody, intravenous","mechanism":"Binds PD-L1 on tumour and immune cells so it cannot engage PD-1 on T cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/socazolimab/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"trial":[{"id":"nct06459687","kind":"trial","name":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","route":"/trials/nct06459687/"}]}}